nach oben

Erschienen in:

01.04.2013 | Neuro

Albumin-binding MR blood pool contrast agent improves diagnostic performance in human brain tumour: comparison of two contrast agents for glioblastoma

verfasst von: Josep Puig, Gerard Blasco, Marco Essig, Josep Daunis-i-Estadella, Gemma Laguillo, Ana María Quiles, Sebastián Remollo, Karsten Bergmann, Carme Joly, Lluis Bernado, Javier Sánchez-González, Salvador Pedraza

Erschienen in: European Radiology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Objective

We qualitatively and quantitatively compared MRI enhancement obtained with gadofosveset, an albumin-binding blood-pool contrast agent, and with gadobutrol, an extracellular contrast agent, in patients with glioblastoma.

Methods

Thirty-five patients (25 men; 64 ± 14 years) with histologically proven glioblastoma underwent MRI including pre- and post-contrast T1-weighted SE images acquired 5 min after gadobutrol (0.1 mmol/kg) and, 48 h later, images acquired with identical parameters 5 min and 3, 6, and 24 h after gadofosveset (0.03 mmol/kg). Lesion extent, delineation, internal morphology, multifocality, and global diagnostic preference were evaluated quantitatively for the signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), and contrast enhancement (CE).

Results

Mean values of SNR, CNR, and tumour CE were highest 6 h after gadofosveset. Multifocality was seen in 17 (48.6 %) patients; additional lesions had stronger enhancement 6 h after gadofosveset in 12 patients (70.6 %). In 21 (60 %) patients, radiologists’ global preference was highest in images acquired 6 h after gadofosveset (kappa = 0.764). In 22 patients (62.8 %), all qualitative endpoints were better at 5 min after gadobutrol than in images acquired 5 min after gadofosveset injection.

Conclusions

Gadobutrol gives significant tumour enhancement in early postcontrast imaging. However, images acquired 6 h after gadofosveset injection have significantly better diagnostic information endpoints and contrast enhancement.

Key Points

• We compared MRI enhancement with gadofosveset and gadobutrol in patients with glioblastoma.

• Gadobutrol provides better enhancement in early enhanced imaging at 5 min.

• Gadofosveset at 6 h post-injection provides optimal enhancement and diagnostic information endpoints.

• Gadofosveset is feasible for diagnostic quality contrast-enhanced MRI in glioblastoma.

• The contrast medium dose can be reduced without disminishing the image quality using gadofosveset.

Giesel FL, Mehndiratta A, Essig M (2010) High-relaxivity contrast-enhanced magnetic resonance neuroimaging: a review. Eur Radiol 20:2461–2474PubMedCrossRef

Smirniotopoulos JG, Murphy FM, Rushing EJ, Rees JH, Schroeder JW (2007) Patterns of contrast enhancement in the brain and meninges. Radiographics 27:525–551PubMedCrossRef

Jensen TR, Schmainda KM (2009) Computer-aided detection of brain tumor invasion using multiparametric MRI. J Magn Reson Imaging 30:481–489PubMedCrossRef

Essig M, Weber MA, von Tengg-Kobligk H, Knopp MV, Yuh WT, Giesel FL (2006) Contrast-enhanced magnetic resonance imaging of central nervous system tumors: agents, mechanisms, and applications. Top Magn Reson Imaging 17:89–106PubMedCrossRef

Colosimo C, Manfredi R, Tartaglione T (1997) Contrast enhancement issues in the MR evaluation of the central nervous system. Eur Radiol Suppl 5:231–237

Tombach B, Heindel W (2002) Value of 1.0-M gadolinium chelates: review of preclinical and clinical data on gadobutrol. Eur Radiol 12:1550–1556PubMedCrossRef

Attenberger UI, Runge VM, Jackson CB et al (2009) Comparative evaluation of lesion enhancement using 1 M gadobutrol vs. 2 conventional gadolinium chelates, all at a dose of 0.1 mmol/kg, in a rat brain tumor model at 3 T. Investig Radiol 44:251–256CrossRef

Mohs AM, Lu ZR (2007) Gadolinium (III)-based blood-pool contrast agents for magnetic resonance imaging: status and clinical potential. Expert Opin Drug Deliv 4:149–164PubMedCrossRef

Farooki A, Narra V, Brown J (2004) Gadofosveset EPIX/Schering. Curr Opin Investig Drugs 5:967–976PubMed

10.

Caravan P (2009) Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action. Acc Chem Res 42:851–862PubMedCrossRef

11.

Seitz RJ, Wechsler W (1987) Immunohistochemical demonstration of serum proteins in human cerebral gliomas. Acta Neuropathol 73:145–152PubMedCrossRef

12.

Essig M, Rohrer M, Giesel F et al (2010) Human brain tumor imaging with a protein-binding MR contrast agent: initial experience. Eur Radiol 20:218–226PubMedCrossRef

13.

Maravilla KR, Maldjian JA, Schmalfuss IM et al (2006) Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology 240:389–400PubMedCrossRef

14.

Fleiss JL (1981) Statistical methods for rates and proportions, 2nd edn. Wiley, New York

15.

Adzamli K, Yablonskiy DA, Chicoine MR et al (2003) Albumin-binding MR blood pool agents as MRI contrast agents in an intracranial mouse glioma model. Magn Reson Med 49:586–590PubMedCrossRef

16.

Wintersperger BJ, Runge VM, Tweedle MF, Jackson CB, Reiser MF (2009) Brain tumor enhancement in magnetic resonance imaging: dependency on the level of protein binding of applied contrast agents. Investig Radiol 44:89–94CrossRef

17.

Els T, Bockhorst K, Hoehn-Berlage M (1993) NMR contrast enhancement of brain tumours: Comparison of the BBB tracer GdDTPA and tumour-selective contrast agent MnTPPS. MAGMA 1:126–133CrossRef

18.

Hahn G, Sorge I, Gruhn B et al (2009) Pharmacokinetics and safety of gadobutrol enhanced magnetic resonance imaging in pediatric patients. Investig Radiol 44:776–783CrossRef

19.

Senft C, Bink A, Franz K, Vatter H, Gasser T, Seifert V (2011) Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol 12:997–1003PubMedCrossRef

20.

Yuh WT, Tali ET, Nguyen HD, Simonson TM, Mayr NA, Fisher DJ (1995) The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis. AJNR Am J Neuroradiol 16:373–380PubMed

Titel: Albumin-binding MR blood pool contrast agent improves diagnostic performance in human brain tumour: comparison of two contrast agents for glioblastoma
verfasst von: Josep Puig
Gerard Blasco
Marco Essig
Josep Daunis-i-Estadella
Gemma Laguillo
Ana María Quiles
Sebastián Remollo
Karsten Bergmann
Carme Joly
Lluis Bernado
Javier Sánchez-González
Salvador Pedraza
Publikationsdatum: 01.04.2013
Verlag: Springer-Verlag
Erschienen in: European Radiology / Ausgabe 4/2013
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-012-2678-9

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Albumin-binding MR blood pool contrast agent improves diagnostic performance in human brain tumour: comparison of two contrast agents for glioblastoma